Ginkgo Datapoints partners with Lilly TuneLab on AI-driven drug discovery lab data generation

By Public Technologies
  • Ginkgo Bioworks struck an agreement with Lilly’s TuneLab platform to provide lab data generation services for AI-driven drug discovery.
  • Ginkgo Datapoints will run small-molecule ADME testing plus antibody developability screening for TuneLab participants.
  • Standardized assays aim to feed ML-ready datasets into TuneLab models, tightening the design-to-lab validation cycle.
  • TuneLab companies can submit Datapoints-generated results to access additional platform model benefits.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief on September 16, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk